Telix Pharmaceuticals Limited: FDA Approves Expanded Indicat

MELBOURNE, Australia, March 16, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the United States Food and Drug Administration (FDA) has

Related Keywords

Australia , Japan , United States , United Kingdom , Belgium , Melbourne , Victoria , Canada , Switzerland , Australian , American , Dennis Riedl , Kyahn Williamson , Kevin Richardson , Oliver Sartor , Telix Pharmaceuticals , Linkedin , Drug Administration , Tulane Cancer Center , Australian Securities Exchange , Novartis , Prnewswire Telix Pharmaceuticals Limited , Australian Therapeutic Goods Administration , Corporate Communications , Health Canada , American Cancer Society , Pharmaceuticals Limited , United States Food , New Drug Application , Chief Executive Officer , Telix Americas , Medical Director , Telix Pharmaceuticals Limited , Emission Tomography , Computed Tomography , Cancer Society , Key Statistics , Prostate Cancer , Telix , Pharmaceuticals , Imited , Pproves , Xpanded , Indication , Lluccix , Nclude , Patient , Election , Visma , Directed , Adioligand , Therapy ,